A Multicentre, Comparative, Randomised, Double-blind, Double-dummy Clinical Trial on the Efficacy and Safety of Condrosulf Versus Celebrex and Versus a Placebo in the Treatment of Knee Osteoarthritis

Trial Profile

A Multicentre, Comparative, Randomised, Double-blind, Double-dummy Clinical Trial on the Efficacy and Safety of Condrosulf Versus Celebrex and Versus a Placebo in the Treatment of Knee Osteoarthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Chondroitin sulfate (Primary) ; Celecoxib
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms CONCEPT
  • Sponsors IBSA
  • Most Recent Events

    • 14 Jun 2017 According to a Bioiberica media release, results from this and the MOSAIC trial will be presented at the 2017 Annual European Congress of Rheumatology.
    • 13 Jun 2016 Results presented at the European Congress of Rheumatology (EULAR 2016), as per IBSA international media release.
    • 13 Jun 2016 Primary endpoint has been met. (Pain (VAS in mm) (Chondroitin-sulfate vs Placebo) [ Time Frame: Day 1 and Day 182 ] [ Designated as safety issue: No ]), as per IBSA international media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top